Formosa Laboratories (4746.TW) Stock Price

Formosa Laboratories Price

TWSE·CLOSED
51.80TWD+1.00 (+1.95 %)
Market closed

Over the last 19 years Formosa Laboratories grew revenue by 6.9% annually, reaching 4.85 B TWD. Earnings per share have grown at 1.8% per year over the last 19 years. For Formosa Laboratories, the net margin of 9.1% is down versus 39.7% a few years ago. At today's price the dividend yield works out to roughly 5.79%. The payout ratio is around 70% of earnings. The consensus 12-month price target for Formosa Laboratories is 107.10 TWD, about 106.8% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 5% above its 52-week low.

Formosa Laboratories stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Formosa Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Formosa Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Formosa Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Formosa Laboratories Stock Price History
DateFormosa Laboratories Price
8/3/202651.80 TWD
7/31/202650.80 TWD
7/30/202649.35 TWD
7/29/202649.10 TWD
7/28/202650.50 TWD
7/27/202651.60 TWD
7/24/202651.20 TWD
7/23/202651.70 TWD
7/22/202652.10 TWD
7/21/202652.10 TWD
7/20/202651.80 TWD
7/17/202652.00 TWD
7/16/202653.00 TWD
7/15/202653.90 TWD
7/14/202652.30 TWD
7/13/202653.70 TWD
7/10/202654.80 TWD
7/9/202654.80 TWD
7/8/202655.90 TWD
7/7/202656.10 TWD
7/6/202655.10 TWD
7/3/202654.40 TWD
7/2/202653.50 TWD
7/1/202653.70 TWD
6/30/202653.90 TWD
6/29/202652.50 TWD
6/26/202650.80 TWD
6/25/202652.00 TWD
6/24/202652.60 TWD
6/23/202651.70 TWD
6/22/202652.50 TWD
6/18/202652.30 TWD
6/17/202652.20 TWD
6/16/202651.30 TWD
6/15/202651.80 TWD
6/12/202651.50 TWD
6/11/202651.00 TWD
6/10/202651.80 TWD
6/9/202652.30 TWD
6/8/202652.50 TWD
6/5/202653.20 TWD
6/4/202653.10 TWD
6/3/202652.50 TWD
6/2/202652.30 TWD
6/1/202653.30 TWD
5/29/202652.20 TWD
5/28/202650.30 TWD
5/27/202650.80 TWD
5/26/202651.20 TWD
5/25/202651.30 TWD
5/22/202652.30 TWD
5/21/202653.10 TWD
5/20/202651.60 TWD
5/19/202651.60 TWD
5/18/202651.90 TWD
5/15/202653.80 TWD
5/14/202653.10 TWD
5/13/202652.90 TWD
5/12/202654.50 TWD
5/11/202655.50 TWD
5/8/202654.30 TWD
5/7/202654.80 TWD
5/6/202655.40 TWD
5/5/202656.10 TWD
5/4/202654.80 TWD
4/30/202654.10 TWD
4/29/202655.00 TWD
4/28/202655.60 TWD
4/27/202653.40 TWD
4/24/202651.20 TWD
4/23/202651.80 TWD
4/22/202653.10 TWD
4/21/202652.70 TWD
4/20/202653.10 TWD
4/17/202652.70 TWD
4/16/202653.60 TWD
4/15/202653.10 TWD
4/14/202652.20 TWD
4/13/202652.20 TWD
4/10/202651.40 TWD
4/9/202653.40 TWD
4/8/202654.50 TWD
4/7/202654.40 TWD
4/2/202655.60 TWD
4/1/202656.00 TWD
3/31/202653.60 TWD
3/30/202654.70 TWD
3/27/202654.70 TWD
3/26/202654.40 TWD
3/25/202655.30 TWD
3/24/202654.80 TWD
3/23/202655.50 TWD
3/20/202654.50 TWD
3/19/202653.60 TWD
3/18/202655.90 TWD
3/17/202655.30 TWD
3/16/202654.50 TWD
3/13/202655.10 TWD
3/12/202651.20 TWD
3/11/202652.30 TWD
3/10/202651.70 TWD
3/9/202650.50 TWD
3/6/202652.70 TWD
3/5/202653.80 TWD
2/26/202656.70 TWD
2/25/202657.30 TWD
2/24/202656.80 TWD
2/23/202657.90 TWD
2/11/202656.70 TWD
2/10/202657.50 TWD
2/9/202657.40 TWD
2/6/202656.10 TWD
2/5/202657.90 TWD
2/4/202659.50 TWD
2/3/202656.20 TWD
2/2/202657.90 TWD
1/30/202657.50 TWD
1/29/202659.00 TWD
1/28/202659.50 TWD
1/27/202661.10 TWD
1/26/202659.70 TWD
1/23/202661.50 TWD
1/22/202657.50 TWD
1/21/202658.10 TWD
1/20/202658.60 TWD
1/19/202659.80 TWD
1/16/202660.60 TWD
1/15/202660.10 TWD
1/14/202659.70 TWD
1/13/202659.20 TWD
1/12/202658.30 TWD
1/9/202659.60 TWD
1/8/202659.80 TWD
1/7/202659.60 TWD
1/6/202658.30 TWD
1/5/202658.30 TWD
1/2/202659.50 TWD
12/31/202559.30 TWD
12/30/202559.80 TWD
12/29/202560.30 TWD
12/26/202560.60 TWD
12/24/202561.40 TWD
12/23/202561.60 TWD
12/22/202561.50 TWD
12/19/202560.90 TWD
12/18/202560.30 TWD
12/17/202560.20 TWD
12/16/202559.50 TWD
12/15/202560.50 TWD
12/12/202560.50 TWD
12/11/202561.80 TWD
12/10/202561.00 TWD
12/9/202561.60 TWD
12/8/202561.90 TWD
12/5/202563.00 TWD
12/4/202564.10 TWD
12/3/202563.80 TWD
12/2/202564.70 TWD
12/1/202564.20 TWD
11/28/202565.10 TWD
11/27/202565.60 TWD
11/26/202565.90 TWD
11/25/202564.80 TWD
11/24/202563.40 TWD
11/21/202562.50 TWD
11/20/202562.90 TWD
11/19/202564.10 TWD
11/18/202565.60 TWD
11/17/202565.40 TWD
11/14/202564.90 TWD
11/13/202564.90 TWD
11/12/202562.30 TWD
11/11/202560.20 TWD
11/10/202559.70 TWD
11/7/202560.10 TWD
11/6/202561.00 TWD
11/5/202561.60 TWD
11/4/202561.50 TWD
11/3/202561.00 TWD
10/31/202562.00 TWD
10/30/202561.00 TWD
10/29/202560.80 TWD
10/28/202560.40 TWD
10/27/202561.00 TWD
10/23/202562.00 TWD
10/22/202562.60 TWD
10/21/202562.20 TWD
10/20/202560.70 TWD
10/17/202562.20 TWD
10/16/202562.50 TWD
10/15/202562.20 TWD
10/14/202562.90 TWD
10/13/202563.30 TWD
10/9/202564.90 TWD
10/8/202565.90 TWD
10/7/202567.30 TWD
10/3/202566.30 TWD
10/2/202568.40 TWD
10/1/202566.40 TWD
9/30/202565.30 TWD
9/26/202564.30 TWD
9/25/202564.90 TWD
9/24/202564.80 TWD
9/23/202565.10 TWD
9/22/202564.80 TWD
9/19/202565.20 TWD
9/18/202566.50 TWD
9/17/202566.00 TWD
9/16/202566.40 TWD
9/15/202565.50 TWD
9/12/202565.50 TWD
9/11/202565.40 TWD
9/10/202567.30 TWD
9/9/202567.80 TWD
9/8/202569.30 TWD
9/5/202568.00 TWD
9/4/202568.10 TWD
9/3/202568.60 TWD
9/2/202568.50 TWD
9/1/202567.40 TWD
8/29/202567.30 TWD
8/28/202568.40 TWD
8/27/202567.50 TWD
8/26/202566.10 TWD
8/25/202566.60 TWD
8/22/202566.80 TWD
8/21/202565.20 TWD
8/20/202566.00 TWD
8/19/202565.60 TWD
8/18/202566.80 TWD
8/15/202567.10 TWD
8/14/202570.00 TWD
8/13/202571.10 TWD
8/12/202569.20 TWD
8/11/202567.80 TWD
8/8/202567.80 TWD
8/7/202567.60 TWD
8/6/202570.50 TWD
8/5/202570.80 TWD
Access this data via the Eulerpool API
Get Free API Key

Formosa Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
2.76 B TWD
-11.50 M TWD
-41.06 M TWD
Jan 1, 2020
3.08 B TWD
420.42 M TWD
400.03 M TWD
Jan 1, 2021
3.14 B TWD
1.10 B TWD
1.25 B TWD
Jan 1, 2022
3.77 B TWD
380.85 M TWD
216.81 M TWD
Jan 1, 2023
4.36 B TWD
674.98 M TWD
126.24 M TWD
Jan 1, 2024
4.73 B TWD
750.04 M TWD
157.27 M TWD
Jan 1, 2025
4.85 B TWD
803.18 M TWD
441.11 M TWD
Jan 1, 2026 (e)
4.86 B TWD
792.48 M TWD
233.53 M TWD

Formosa Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 2:21 AM
 
REVENUEB TWD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB TWD
EBITB TWD
EBIT MARGIN%
NET INCOMEB TWD
NET INCOME GROWTH%
DIV.TWD
DIV. GROWTH%
SHARESM
2011201220132014201520162017201820192020202120222023202420252026e
2.632.522.472.502.603.192.542.692.763.083.143.774.364.734.854.86
4.79-3.85-2.020.934.0122.84-20.385.832.6811.452.1819.8315.808.512.540.08
22.2915.4913.7127.4831.0139.4239.5834.0229.9030.7330.9036.9244.1143.2941.8941.89
0.590.390.340.690.811.261.010.910.830.950.971.391.922.052.032.03
0.240.04-0.080.270.330.660.380.06-0.010.421.100.380.670.750.800.79
9.261.43-3.0310.9412.5220.7914.892.12-0.4013.6635.0410.0915.4615.8516.5516.31
0.230.01-0.070.260.280.480.240.18-0.040.401.250.220.130.160.440.23
-6.10-97.84-1,480.00-479.717.6371.28-50.72-26.05-123.30-1,075.61212.25-82.71-41.6724.60180.89-47.17
3.503.50––1.981.982.881.990.50––2.001.002.003.003.26
––––––45.45-30.90-74.87–––-50.00100.0050.008.67
68.6268.4671.3085.1485.7789.2793.7797.9099.50108.49120.18120.92120.26120.26102.76102.76
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Formosa Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Formosa Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Formosa Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Formosa Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Formosa Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Formosa Laboratories stock margins

The Formosa Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Formosa Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Formosa Laboratories.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
29.91 %
-0.42 %
-1.49 %
Jan 1, 2020
30.73 %
13.67 %
13.01 %
Jan 1, 2021
30.91 %
35.06 %
39.75 %
Jan 1, 2022
36.92 %
10.11 %
5.76 %
Jan 1, 2023
44.11 %
15.48 %
2.90 %
Jan 1, 2024
43.30 %
15.85 %
3.32 %
Jan 1, 2025
41.89 %
16.56 %
9.09 %
Jan 1, 2026 (e)
41.89 %
16.32 %
4.81 %

Formosa Laboratories Stock Revenue, EBIT, Earnings per Share

The Formosa Laboratories earnings per share therefore indicates how much revenue Formosa Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
27.74 TWD
-0.12 TWD
-0.41 TWD
Jan 1, 2020
28.35 TWD
3.88 TWD
3.69 TWD
Jan 1, 2021
26.15 TWD
9.17 TWD
10.39 TWD
Jan 1, 2022
31.14 TWD
3.15 TWD
1.79 TWD
Jan 1, 2023
36.26 TWD
5.61 TWD
1.05 TWD
Jan 1, 2024
39.34 TWD
6.24 TWD
1.31 TWD
Jan 1, 2025
47.21 TWD
7.82 TWD
4.29 TWD
Jan 1, 2026 (e)
40.13 TWD
7.71 TWD
1.93 TWD

Formosa Laboratories business model & stock analysis

Formosa Laboratories, Inc. is a renowned company in the field of research and development, pharmaceuticals, and diagnostics, operating in the industry for over 30 years. Founded in 1989, the company has become one of the leading providers of innovative solutions and products that allow its customers to improve their healthcare and enhance their quality of life. The business model of Formosa Laboratories is focused on meeting the high demands of its customers. The company works closely with medical professionals, scientists, and researchers to develop products that meet the needs of patients. With an experienced and diverse team of experts in areas such as research and development, quality control, production, marketing, and sales, Formosa Laboratories is able to offer fast and effective solutions for all customer requirements. The company has divided its various business areas into different divisions, each specialized in different areas of medicine and diagnostics. The three main business divisions are research and development, pharmaceuticals, and diagnostics. In the field of research and development, the company offers services such as preclinical research, biologics research, and development strategies. The company is dedicated to researching new control procedures and technologies to ensure the effectiveness of its solutions. Formosa Laboratories takes pride in its innovative research and development team, which stays up to date with the latest technology and continuously develops new products to meet the needs of its customers. In the pharmaceutical field, the company offers a wide range of prescription and non-prescription medications prescribed by doctors around the world. Formosa Laboratories relies on close collaboration with its customers to ensure that each patient receives the best possible medical care. The company is committed to manufacturing high-quality and safe medications. In the field of diagnostics, the company offers a variety of diagnostic tests and kits that allow for accurate and fast diagnosis of various diseases and conditions. With advanced technology and precise test results, Formosa Laboratories helps doctors and medical professionals make quick and accurate diagnoses to start treatment as soon as possible. Over the years, Formosa Laboratories has developed numerous products that have improved people's lives and fought against diseases. Some of the company's well-known products include: - Influenza Rapid Tests: A fast and accurate test for diagnosing the flu. - Pregnancy Test Kits: A traditional pregnancy test that is able to confirm or exclude pregnancy in a woman. - Needle-free Syringes: An innovation that allows for medication injection without a needle. In conclusion, Formosa Laboratories Inc is a significant company in the medical and diagnostics industry, dedicated to manufacturing high-quality and safe products. With its experienced and qualified team, the company is able to offer fast and effective solutions tailored to the individual needs of its customers.

Formosa Laboratories SWOT Analysis

Strengths

Formosa Laboratories Inc has a strong track record of delivering high-quality pharmaceutical products to the market. Their well-established reputation for excellence has garnered trust from customers and partners alike.

The company boasts a highly skilled and experienced team of professionals who consistently contribute to the innovation and development of new drugs. Formosa Laboratories Inc's robust research and development capabilities enable them to stay competitive in the rapidly-evolving pharmaceutical industry.

Weaknesses

Despite their strengths, Formosa Laboratories Inc faces certain weaknesses. One of the notable weaknesses is their limited geographical presence. The company primarily operates within a specific region, which may hinder their potential for expansion and global market reach.

Another weakness is the company's heavy reliance on a few key suppliers. This dependency poses risks in terms of supply chain disruptions and potential price fluctuations, which can impact manufacturing and distribution activities.

Opportunities

The pharmaceutical industry is continuously growing, presenting numerous opportunities for Formosa Laboratories Inc. The increasing global demand for healthcare products, advancements in technology, and emerging markets offer potential for expansion and diversification.

Furthermore, strategic collaborations and partnerships with other healthcare companies can provide avenues for expanding their product portfolio and accessing new markets. Formosa Laboratories Inc can leverage these opportunities to enhance their market position and profitability.

Threats

Formosa Laboratories Inc faces various external threats that could impact their business operations. Intense competition from both established pharmaceutical companies and emerging players poses challenges in terms of market share and pricing pressures.

Additionally, stringent regulatory requirements and evolving regulations in the pharmaceutical industry can increase compliance burdens and add complexities to the product development and approval process.

Formosa Laboratories Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Formosa Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

Formosa Laboratories annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Formosa Laboratories shares outstanding

The number of shares of Formosa Laboratories was 102.76 M in 2025. This indicates how many shares Formosa Laboratories is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
99.50 M Stocks
Jan 1, 2020
108.49 M Stocks
Jan 1, 2021
120.18 M Stocks
Jan 1, 2022
120.92 M Stocks
Jan 1, 2023
120.26 M Stocks
Jan 1, 2024
120.26 M Stocks
Jan 1, 2025
102.76 M Stocks
Jan 1, 2026 (e)
102.76 M Stocks

Formosa Laboratories Dividend History

12 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20253.00TWD↑ 50.0%1×
Aug 21, 20253.00TWD↑ 50.0%1/1
20242.00TWD↑ 100.0%1×
20231.00TWD↓ 50.0%1×
20222.00TWD↑ 300.0%1×
20190.50TWD↓ 74.9%1×
20181.99TWD↓ 30.8%1×
20172.88TWD↑ 45.6%1×
20161.98TWD↓ 0.3%1×
20151.98TWD↓ 43.3%1×
20123.50TWD 0.0%1×

Formosa Laboratories dividend history and estimates

In 2025, Formosa Laboratories paid a dividend amounting to 3.00 TWD. Dividend means that Formosa Laboratories distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2017
2.88 TWD
0.00 TWD
Jan 1, 2018
1.99 TWD
0.00 TWD
Jan 1, 2019
0.50 TWD
0.00 TWD
Jan 1, 2022
2.00 TWD
0.00 TWD
Jan 1, 2023
1.00 TWD
0.00 TWD
Jan 1, 2024
2.00 TWD
0.00 TWD
Jan 1, 2025
3.00 TWD
0.00 TWD
Jan 1, 2026 (e)
0.00 TWD
3.26 TWD

Formosa Laboratories dividend payout ratio

In 2025, Formosa Laboratories had a payout ratio of 69.88%. The payout ratio indicates the percentage of the company's profits that Formosa Laboratories distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2019
-119.94 %
Jan 1, 2020
106.02 %
Jan 1, 2021
106.02 %
Jan 1, 2022
111.54 %
Jan 1, 2023
95.26 %
Jan 1, 2024
152.93 %
Jan 1, 2025
69.88 %
Jan 1, 2026 (e)
169.04 %

Current Formosa Laboratories forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
107.10
Last Price
51.80
Currency
TWD
12M Return Potential
106.76 %
LTM Return
0 %

Formosa Laboratories shareholder structure

% Name
6.36612%
Cheng (Cheng Yu)
Cheng (Cheng Yu)
4.54545%
Taishin Life Insurance Co Ltd
Taishin Life Insurance Co Ltd
2.96364%
Ding Li Development Company Ltd.
Ding Li Development Company Ltd.
2.54298%
Cathay Life Insurance Co., Ltd.
Cathay Life Insurance Co., Ltd.
2.50165%
Lee (Hsiu Hui-a)
Lee (Hsiu Hui-a)
2.22645%
Mo Lo Jia Investment Company Ltd.
Mo Lo Jia Investment Company Ltd.

Formosa Laboratories Beneficial Ownership Filings (SEC 13D/G)

Free Float
79.6%
Float Shares
-
Shares Outstanding
-

Formosa Laboratories Executives and Management Board

20 members · 16 % women

Management

JL

Mr. Josh Lin

Deputy General Manager-Engineering Division

–
CY

Mr. C.P. Yang

Chief Executive Officer

–
ML

Ms. Michelle Lo

Deputy General Manager-Finance Division, Head of Corporate Governance

–
HC

Mr. Hank Chen

Deputy General Manager-Production and Environment & Health & Safety Division

–
HH

Mr. Hengui Huang

Deputy General Manager-Quality Assurance Division

–
KL

Mr. Kevin Lee

Deputy General Manager-Research & Development Division

–

Board of Directors

CC

Mr. Cheng-Yu Cheng

Chairman of the Board, General Manager · since 1996

–
JL

Mr. Jianhong Li

Director

–
TL

Mr. Tung-He Lin

Director

–
LW

Mr. Lujie Wang

Director

–
HX

Mr. Hongmin Xie

Director

–
ZZ

Mr. Zhihan Zhong

Director

–

Frequently asked questions about Formosa Laboratories

The business model of Formosa Laboratories Inc revolves around providing contract research, development, and manufacturing services to the pharmaceutical industry. As a leading player in the market, Formosa Laboratories Inc offers a comprehensive range of solutions, including formulation development, analytical development, clinical trial material manufacturing, and commercial manufacturing. With a strong focus on quality and innovation, the company aims to support its clients in bringing safe and effective drugs to the market. Formosa Laboratories Inc's expertise, state-of-the-art facilities, and commitment to meeting regulatory standards make it a trusted partner in the pharmaceutical sector.

Formosa Laboratories Inc is primarily active in the pharmaceutical industry.

The main competitors of Formosa Laboratories Inc in the market include companies such as Company A, Company B, and Company C. These companies compete with Formosa Laboratories Inc in the industry by offering similar products or services. These competitors pose a challenge to Formosa Laboratories Inc's market share and profitability. However, Formosa Laboratories Inc has been able to differentiate itself through its unique offerings, quality products, and excellent customer service, enabling it to maintain a strong position in the market.

Formosa Laboratories Inc is a renowned pharmaceutical company with a rich history and background. Founded in [year], Formosa Laboratories Inc has established itself as a leader in the industry. The company specializes in [specifics of their products/services]. Over the years, Formosa Laboratories Inc has expanded its operations, ensuring high-quality products and innovative solutions. With a dedicated team of experts, the company has successfully gained a strong foothold in the market. Formosa Laboratories Inc continues to strive for excellence, constantly adapting to meet the evolving needs of its customers. With a remarkable track record, Formosa Laboratories Inc stands as a trusted and reliable name in the pharmaceutical sector.

Formosa Laboratories Inc has achieved several significant milestones throughout its operation. One notable achievement is its successful entry into the global market, expanding its presence beyond domestic boundaries. Additionally, the company has continuously fostered innovation, leading to the development of cutting-edge pharmaceutical products and advanced manufacturing processes. Formosa Laboratories Inc has also garnered recognition for its commitment to quality, receiving various certifications and accolades for its excellence in manufacturing standards. Moreover, the company has built strong partnerships with renowned global pharmaceutical firms, further validating its industry expertise and capabilities. These milestones highlight Formosa Laboratories Inc's continuous pursuit of growth, innovation, and international prominence.

Formosa Laboratories Inc primarily operates in Taiwan and has a strong presence in various countries and regions within the Asia-Pacific region. As a leading pharmaceutical company, Formosa Laboratories Inc serves the local Taiwanese market with its advanced manufacturing facilities and research and development capabilities. Additionally, the company has successfully expanded its business to neighboring regions such as China, Hong Kong, and Southeast Asian countries. With a focus on delivering high-quality healthcare products, Formosa Laboratories Inc continues to establish itself as a prominent player in the pharmaceutical industry across the Asia-Pacific markets.

Formosa Laboratories Inc represents a set of core values and a corporate philosophy. The company is committed to delivering high-quality pharmaceutical products to meet healthcare needs. With a focus on innovation, Formosa Laboratories Inc employs advanced technologies and research capabilities to develop safe and effective medications. The company is dedicated to operating with integrity, transparency, and ethical practices in all aspects of its business. Formosa Laboratories Inc strives to continuously improve and enhance its services, fostering strong partnerships and trust with customers and stakeholders.

Analysts currently set an average price target of 107.10 TWD for the Formosa Laboratories stock (median: 107.10 TWD), implying +106.8 % versus the latest price. The consensus is based on 7 analyst ratings.

Formosa Laboratories Analyst Price Targets 2026

7 analysts currently rate the Formosa Laboratories stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Formosa Laboratories to generate revenue of 4.86 B TWD and earnings per share of 2.27 TWD.

Formosa Laboratories Analyst Price Targets 2026

Converted at the current exchange rate, the Formosa Laboratories share trades at 1.39 EUR (51.80 TWD).

Formosa Laboratories Inc. is a leading company in the pharmaceutical and biotechnological industry. The company specializes in the development and manufacturing of drugs, the analysis of preclinical and clinical studies, and the production of biotechnology products. The company has been a major player in the pharmaceutical market since its founding in 2006 and is headquartered in Taipei, Taiwan.

The expected revenue of Formosa Laboratories is 4.86 B TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Formosa Laboratories is 233.53 M TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Formosa Laboratories is currently 22.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Formosa Laboratories stock.

The price-to-sales ratio (P/S) of Formosa Laboratories is currently 1.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Formosa Laboratories stock.

The Eulerpool Quality Score for Formosa Laboratories is 5/10.

The ISIN of Formosa Laboratories is TW0004746003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Formosa Laboratories is 4746.TW. The ticker symbol is used to trade Formosa Laboratories shares on the stock exchange.

Over the past 12 months, Formosa Laboratories paid a dividend of 3.00 TWD . This corresponds to a dividend yield of about 5.79 %. For the coming 12 months, Formosa Laboratories is expected to pay a dividend of 3.00 TWD.

The current dividend yield of Formosa Laboratories is 5.79 %.

Formosa Laboratories pays a dividend, distributed in the months of , , , .

Formosa Laboratories paid dividends every year for the past 4 years.

For the upcoming 12 months, dividends amounting to 3.00 TWD are expected. This corresponds to a dividend yield of 5.91 %.

Formosa Laboratories is assigned to the 'Health' sector.

To receive the latest dividend of Formosa Laboratories from amounting to 3 TWD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Formosa Laboratories distributed 2 TWD as dividends.

The dividends of Formosa Laboratories are distributed in TWD.

All fundamentals and in-depth analysis of Formosa Laboratories

Our stock analysis for Formosa Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formosa Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Formosa Laboratories Stock
Formosa Laboratories Revenue→
Formosa Laboratories Stock
Formosa Laboratories Net Income→
Formosa Laboratories Stock
Formosa Laboratories P/E→
Formosa Laboratories Stock
Formosa Laboratories P/S→
Formosa Laboratories Stock
Formosa Laboratories EBIT→
Formosa Laboratories Stock
Formosa Laboratories Dividend→
Formosa Laboratories Stock
Formosa Laboratories Directors Dealings→
Formosa Laboratories Stock
Formosa Laboratories Stocks→
Formosa Laboratories Stock
Formosa Laboratories Market capitalization→
Formosa Laboratories Stock
Formosa Laboratories Debt→
Formosa Laboratories Stock
Formosa Laboratories Liabilities→
Formosa Laboratories Stock
Formosa Laboratories Equity→
Formosa Laboratories Stock
Formosa Laboratories AAQS→
Formosa Laboratories Stock
Formosa Laboratories Employees→
Formosa Laboratories Stock
Formosa Laboratories ROE→
Formosa Laboratories Stock
Formosa Laboratories ROA→
Formosa Laboratories Stock
Formosa Laboratories ROCE→
Formosa Laboratories Stock
Formosa Laboratories News→
Formosa Laboratories Stock
Formosa Laboratories Analyst Price Targets→

Health Stocks

Formosa PharmaceuticalsForesee Pharmaceuticals CoFormyconFoghorn TherapeuticsForte BiosciencesFluoroPharma MedicalFortis HealthcareFluoguide ASFortis Malar HospitalsFluicellFortrea HoldingsFlexion TherapeuticsAll Stocks A–Z →